Editor's note

This ExpertREACT article was originally published on 9 May 2011. Market analysis, epidemiological data and pipeline statuses described reflect the state of knowledge at that date.

A rapidly growing global disease burden

Dengue affects populations across more than 100 countries, with the Pediatric Dengue Vaccine Initiative (PDVI) estimating 70-500 million dengue infections per year of which approximately 36 million translate to symptomatic dengue fever (DF). DF is an acute self-limiting febrile illness characterised by fever, rash and severe myalgia. In a small minority of patients, severe manifestations including dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) may be fatal without rapid supportive therapy, accounting for an estimated 21,000 deaths annually. A large proportion of these deaths occur in children under 15 years. All four dengue serotypes (DEN1-4) are now co-circulating in many parts of the world, with secondary infection by a different serotype a major driver of severe disease through antibody-dependent enhancement.

The total reported cases of dengue fever and DHF in three major WHO regions had quadrupled since 2000, driven by environmental factors including rapidly increasing urbanisation and the extensive distribution of the Aedes aegypti vector. A Brandeis University cost analysis estimated that dengue costs countries across the Americas region between $1-4bn per year, encompassing direct and indirect costs of hospitalised and ambulatory cases as well as vector control - exceeding estimated costs for HPV and rotavirus for which vaccines are already licensed.

Annual dengue deaths
~21,000
Estimated annual deaths from dengue haemorrhagic fever and dengue shock syndrome, predominantly in children under 15 years

The adult private sector as commercial cornerstone

VacZine Analytics' new market modelling analysis for dengue highlighted a key commercial insight: the adult private sector would be essential to any dengue vaccine manufacturer's commercial success. While paediatric national immunisation programme (NIP) routes were the obvious precedent from other vaccine categories, the global distribution of dengue disease and the demographics of affected populations in endemic and travel settings pointed strongly towards adult private-market demand as the primary early revenue source. The analysis positioned dengue vaccines as a potentially very large commercial opportunity - but one where the pricing and market access strategies chosen by manufacturers would largely determine whether the social good could be monetised at scale.